|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
BEFREE |
In this review, we will discuss studies of the roles of VGF using transgenic mice and its relevance to pathologies in major depressive disorder and schizophrenia.
|
31037515 |
2019 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
BEFREE |
In our previous study, VGF-overexpressing mice exhibited schizophrenia-like behaviors and smaller brain weights.
|
30460640 |
2019 |
|
Schizophrenia
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of VGF may be implicated in the pathophysiology of schizophrenia and abnormalities of dopaminergic signaling.
|
29653412 |
2018 |
|
Schizophrenia
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Patients with depression and bipolar disorder have lower-than-normal levels of VGF, whereas patients with schizophrenia and other cohorts of patients with depression have higher-than-normal levels.
|
28680036 |
2017 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
BEFREE |
"Hence, we aimed to better investigate the involvement of the VGF peptides in schizophrenia by studying their localization in the brain regions relevant for the disease, and revealing their possible modulations in response to certain neuronal alterations occurring in schizophrenia".
|
28626390 |
2017 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
BEFREE |
In a sample of 245 nuclear families (n=1074) originating from the same geographical region as the families revealing the linkage, SNP and microsatellite association analyses of the four regional candidate genes, GRM3, RELN, SEMA3A and VGF, revealed no significant association to the clinical diagnosis of schizophrenia.
|
17684500 |
2008 |
|
Mental Depression
|
0.340 |
Biomarker
|
disease |
BEFREE |
The neuropeptide precursor VGF (non-acronymic) plays a critical role in depression and antidepressant efficacy in hippocampus and nucleus accumbens, however its function in vmPFC has not been investigated.
|
30504797 |
2019 |
|
Depressive disorder
|
0.340 |
Biomarker
|
disease |
BEFREE |
The neuropeptide precursor VGF (non-acronymic) plays a critical role in depression and antidepressant efficacy in hippocampus and nucleus accumbens, however its function in vmPFC has not been investigated.
|
30504797 |
2019 |
|
Mental Depression
|
0.340 |
Biomarker
|
disease |
BEFREE |
These adult VGF-overexpressing mice showed (a) hyperactivity, working memory impairment, a higher depressive state, and lower sociality compared with wild-type mice; (b) lower brain weight without a change in body weight; (c) increased lateral ventricle volume compared with wild-type mice; and (d) striatal morphological defects.
|
28680036 |
2017 |
|
Depressive disorder
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Patients with depression and bipolar disorder have lower-than-normal levels of VGF, whereas patients with schizophrenia and other cohorts of patients with depression have higher-than-normal levels.
|
28680036 |
2017 |
|
Mental Depression
|
0.340 |
Biomarker
|
disease |
BEFREE |
In this study, we tested the leukocyte mRNA expression levels of genes belonging to glucocorticoid receptor (GR) function (FKBP-4, FKBP-5, and GR), inflammation (interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, macrophage inhibiting factor (MIF), and tumor necrosis factor (TNF)-α), and neuroplasticity (brain-derived neurotrophic factor (BDNF), p11 and VGF), in healthy controls (n=34) and depressed patients (n=74), before and after 8 weeks of treatment with escitalopram or nortriptyline, as part of the Genome-based Therapeutic Drugs for Depression study.
|
22990943 |
2013 |
|
Mental Depression
|
0.340 |
Biomarker
|
disease |
PSYGENET |
In this study, we tested the leukocyte mRNA expression levels of genes belonging to glucocorticoid receptor (GR) function (FKBP-4, FKBP-5, and GR), inflammation (interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, macrophage inhibiting factor (MIF), and tumor necrosis factor (TNF)-α), and neuroplasticity (brain-derived neurotrophic factor (BDNF), p11 and VGF), in healthy controls (n=34) and depressed patients (n=74), before and after 8 weeks of treatment with escitalopram or nortriptyline, as part of the Genome-based Therapeutic Drugs for Depression study.
|
22990943 |
2013 |
|
Depressive disorder
|
0.340 |
Biomarker
|
disease |
BEFREE |
In this study, we tested the leukocyte mRNA expression levels of genes belonging to glucocorticoid receptor (GR) function (FKBP-4, FKBP-5, and GR), inflammation (interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, macrophage inhibiting factor (MIF), and tumor necrosis factor (TNF)-α), and neuroplasticity (brain-derived neurotrophic factor (BDNF), p11 and VGF), in healthy controls (n=34) and depressed patients (n=74), before and after 8 weeks of treatment with escitalopram or nortriptyline, as part of the Genome-based Therapeutic Drugs for Depression study.
|
22990943 |
2013 |
|
Depressive disorder
|
0.340 |
Biomarker
|
disease |
PSYGENET |
In this study, we tested the leukocyte mRNA expression levels of genes belonging to glucocorticoid receptor (GR) function (FKBP-4, FKBP-5, and GR), inflammation (interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-7, IL-8, IL-10, macrophage inhibiting factor (MIF), and tumor necrosis factor (TNF)-α), and neuroplasticity (brain-derived neurotrophic factor (BDNF), p11 and VGF), in healthy controls (n=34) and depressed patients (n=74), before and after 8 weeks of treatment with escitalopram or nortriptyline, as part of the Genome-based Therapeutic Drugs for Depression study.
|
22990943 |
2013 |
|
Mental Depression
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms.
|
20631166 |
2010 |
|
Mental Depression
|
0.340 |
Biomarker
|
disease |
BEFREE |
Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms.
|
20631166 |
2010 |
|
Depressive disorder
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms.
|
20631166 |
2010 |
|
Depressive disorder
|
0.340 |
Biomarker
|
disease |
BEFREE |
Recent studies demonstrate that the neuropeptide VGF (nonacronymic) is regulated in the hippocampus by antidepressant therapies and animal models of depression and that acute VGF treatment has antidepressant-like activity in animal paradigms.
|
20631166 |
2010 |
|
Mental Depression
|
0.340 |
Biomarker
|
disease |
PSYGENET |
We summarize experimental data describing the roles of BDNF, VGF and other neuropeptides in depression and how they may be acting through the generation of new neurons and altered synaptic activity.
|
18983874 |
2009 |
|
Depressive disorder
|
0.340 |
Biomarker
|
disease |
PSYGENET |
We summarize experimental data describing the roles of BDNF, VGF and other neuropeptides in depression and how they may be acting through the generation of new neurons and altered synaptic activity.
|
18983874 |
2009 |
|
Mental Depression
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Although LTP was normal in slices from VGF knock-out mice, LTD could not be induced, and VGF mutant mice were impaired in hippocampal-dependent spatial learning and contextual fear conditioning tasks.
|
18815270 |
2008 |
|
Depressive disorder
|
0.340 |
Biomarker
|
disease |
PSYGENET |
Although LTP was normal in slices from VGF knock-out mice, LTD could not be induced, and VGF mutant mice were impaired in hippocampal-dependent spatial learning and contextual fear conditioning tasks.
|
18815270 |
2008 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
A neuropeptide precursor VGF has potent antidepressant effects and has been reportedly associated with bipolar disorder.
|
24934694 |
2014 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
The dysregulation of VGF in bipolar disorder as well as the behavioral effects of the neuropeptide similar to LiCl suggests that VGF may underlie the pathophysiology of bipolar disorder.
|
20631166 |
2010 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
The dysregulation of VGF in bipolar disorder as well as the behavioral effects of the neuropeptide similar to LiCl suggests that VGF may underlie the pathophysiology of bipolar disorder.
|
20631166 |
2010 |